Sign in

    Jeevan Larson

    Research Analyst at Truist Securities

    Jeevan Larson is an Equity Research Associate at Truist Securities, focused on coverage of healthcare and life sciences companies including CorMedix and Pacira BioSciences. He contributes to the research and analysis of investment opportunities by working closely with senior analysts, supporting earnings calls, and providing insights to institutional investors. Larson began his analyst career at Truist Securities and actively participates in ongoing equity research as evidenced by his direct involvement in quarterly earnings reports. He holds FINRA registration under CRD# 7967909 as a licensed securities professional, operating out of New York.

    Jeevan Larson's questions to ANI PHARMACEUTICALS (ANIP) leadership

    Jeevan Larson's questions to ANI PHARMACEUTICALS (ANIP) leadership • Q4 2024

    Question

    On behalf of Les Sulewski, Jeevan Larson of Truist Securities asked about potential disruptions to the Cortrophin market, specifically inquiring about the threat from synthetic versions or other competitors.

    Answer

    Executive Nikhil Lalwani responded that the ACTH market is in a strong growth phase, with patient numbers still well below historical peaks, indicating a large opportunity. He highlighted that 40% of ANI's prescribers are new to the ACTH category, demonstrating market expansion. He also noted that bringing a generic or biosimilar to market is historically difficult and that the competitive landscape is expected to remain a two-player market focused on building awareness.

    Ask Fintool Equity Research AI